OncoImmunology (Jan 2021)

Beneficial autoimmunity links primary biliary cholangitis to the avoidance of cholangiocarcinoma

  • Jonathan G. Pol,
  • Juliette Paillet,
  • Céleste Plantureux,
  • Guido Kroemer

DOI
https://doi.org/10.1080/2162402X.2021.1968595
Journal volume & issue
Vol. 10, no. 1

Abstract

Read online

It has been an open conundrum why primary sclerosing cholangitis (PSC) is a major risk factor for developing cholangiocarcinoma (CAA), while primary biliary cholangitis (PBC) is not. In mouse models of PSC and PBC, it turned out that the latter condition, an autoimmune disease affecting the bile ducts, reduces transgene-induced cholangiocarcinogenesis, as well as the progression of subcutaneously implanted CCA. This CCA-delaying effect is lost upon depletion of T lymphocytes and involves tumor infiltration by T cell clonotypes that are also found in PBC lesions. Hence, organ-specific autoimmunity may improve immunosurveillance.

Keywords